Healthcare
•3755 stocks
•
Total Market Cap: Loading...
Price Performance Heatmap
5Y Price (Market Cap Weighted)
All Stocks (3755)
| Company | Market Cap | Price |
|---|---|---|
|
HOTH
Hoth Therapeutics, Inc.
HT-001 (oncology supportive care) and HT-KIT/HT-ALZ pipelines place Hoth in oncology/biotech with a focused cancer therapy strategy.
|
$14.45M |
$1.09
|
|
APLT
Applied Therapeutics, Inc.
Applied Therapeutics is a biotech focused on rare diseases, with lead programs in rare metabolic/neurologic conditions (e.g., govorestat for CMT-SORD) and out-licensing efforts in rare disease assets.
|
$14.43M |
$0.10
+0.50%
|
|
CODX
Co-Diagnostics, Inc.
Co-Dx PCR Pro instrument is a diagnostic equipment product directly manufactured by the company.
|
$14.43M |
$0.35
-6.19%
|
|
OSRH
OSR Holdings, Inc.
VAXIMM's lead oncology immunotherapy candidate positions OSRH in the Biotech - Oncology space.
|
$14.29M |
$0.68
+9.65%
|
|
AMS
American Shared Hospital Services
AMS is directly operating outpatient radiation therapy centers (Direct Patient Services) in Rhode Island, Puebla, and other locations.
|
$14.17M |
$2.16
-0.46%
|
|
FBLG
FibroBiologics, Inc. Common Stock
Core business is fibroblast-based cell therapies (CYWC628, CYMS101, CybroCell) in regenerative medicine; directly matches Biotech - Cell Therapy.
|
$14.16M |
$0.35
+5.85%
|
|
SNSE
Sensei Biotherapeutics, Inc.
Sensei's lead asset targets oncology/cancer indications, fitting the Biotech - Oncology category.
|
$13.95M |
$11.37
+2.80%
|
|
BLRX
BioLineRx Ltd.
BioLineRx's lead oncology asset motixafortide (APHEXDA) places the company squarely in oncology with an approved stem cell mobilization therapy and ongoing cancer indications development.
|
$13.84M |
$2.96
-0.50%
|
|
ELTP
Elite Pharmaceuticals, Inc.
Elite focuses on the development, manufacture, and sale of generic drugs across a broad pipeline.
|
$13.82M |
$0.50
|
|
TPST
Tempest Therapeutics, Inc.
Tempest is a clinical-stage biotechnology company focused on oncology with lead and follow-on small molecule cancer programs.
|
$13.81M |
$3.15
-0.16%
|
|
NXGL
NEXGEL, Inc.
NXGEL generates revenue from contract manufacturing of hydrogel-based medical and consumer products.
|
$13.71M |
$1.66
-2.35%
|
|
BCTX
BriaCell Therapeutics Corp.
BriaCell's core focus is oncology immunotherapies, aligning with Biotech - Oncology.
|
$13.71M |
$7.15
-1.79%
|
|
ACUT
Accustem Sciences Inc.
Company plans to offer Laboratory Testing & Advisory Services leveraging existing lab infrastructure and additional sequencing/heritage panels.
|
$13.61M |
$0.81
|
|
PVCT
Provectus Biopharmaceuticals, Inc.
VisiRose EyeCo focuses on ophthalmic topical RBS (PV-305) for infectious keratitis, an ophthalmic drug product.
|
$13.60M |
$0.06
|
|
THAR
Tharimmune, Inc.
THAR directly develops monoclonal antibody therapeutics (e.g., TH023 and IO assets HS1940/HS3215), fitting Monoclonal Antibody Therapeutics.
|
$13.49M |
$2.79
-4.12%
|
|
CFOO
China Foods Holdings Ltd.
The company provides customized wellness consultation programs and related services.
|
$13.45M |
$0.66
|
|
ZCMD
Zhongchao Inc.
ZCMD provides healthcare information services and patient management systems to healthcare professionals and institutions, fitting Healthcare Services & Facilities.
|
$13.43M |
$0.50
-5.20%
|
|
TRIB
Trinity Biotech plc
Directly manufactures glucose monitoring hardware (CGM) and wearable biosensors with an accompanying data platform.
|
$13.33M |
$0.73
-0.97%
|
|
ALUR
Allurion Technologies Inc.
Allurion Balloon is a swallowable medical device used for weight management.
|
$13.04M |
$1.69
-0.88%
|
|
QNRX
Quoin Pharmaceuticals, Ltd.
Lead program targets a rare disease (Netherton Syndrome) and is developed by a biotech focused on rare diseases.
|
$12.57M |
$12.36
-6.05%
|
|
NXL
Nexalin Technology, Inc.
Core product is non-invasive neuromodulation devices for brain stimulation (Gen-2 SYNC, Gen-3 HALO).
|
$12.41M |
$0.71
+0.14%
|
|
KPEA
Kun Peng International Ltd.
The business includes health care equipment-based services and devices, aligning with medical devices & equipment.
|
$12.20M |
$0.05
|
|
LIPO
Lipella Pharmaceuticals Inc.
Lipella's core metastable liposome drug delivery platform enables targeted, localized mucosal drug formulations.
|
$12.20M |
$0.31
|
|
SYBX
Synlogic, Inc.
PKU is a rare metabolic disease and Synlogic's lead programs target rare diseases via a synthetic biology platform.
|
$12.17M |
$1.05
+0.96%
|
|
BMGL
Basel Medical Group Ltd Ordinary Shares
BMGL provides hospital-style healthcare services, including inpatient/outpatient care via clinics and integrated care delivery.
|
$11.69M |
$0.68
+3.39%
|
|
COCP
Cocrystal Pharma, Inc.
Cocrystal Pharma is actively developing antiviral small-molecule therapeutics (CC-42344, CDI-988, CC-31244) for influenza, norovirus/coronavirus, and HCV.
|
$11.28M |
$1.17
+5.91%
|
|
BOLT
Bolt Biotherapeutics, Inc.
Bolt is a clinical-stage biotech focused on oncology immunotherapies, making 'Biotech - Oncology' a core investable theme.
|
$11.15M |
$5.86
+0.77%
|
|
LUDG
Ludwig Enterprises, Inc.
Development of non-invasive diagnostic tests/biomarker-based technology qualifies as medical devices & biometrics.
|
$11.05M |
$0.05
|
|
VASO
Vaso Corporation
Cardiology devices portfolio (EECP systems, Holter monitors, etc.) is a direct product line.
|
$11.05M |
$0.17
|
Showing page 33 of 38 (3755 total stocks)
Loading company comparison...
Loading industry trends...
Loading research report...
